Validation of three BRCA1/2 mutation-carrier probability models Myriad, BRCAPRO and BOADICEA in a population-based series of 183 German families

Familial Cancer

Volumn 11, Issue 2, 2012, Pages 181-188

  Schneegans, S M ^a   Rosenberger, A ^a   Engel, U ^a   Sander, M ^a   Emons, G ^a   Shoukier, M ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

BOADICEA; BRCA1; BRCA2; BRCAPRO; LGRs; Myriad

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC MODEL; GENETIC RISK; GENOMICS; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION GENETIC PARAMETERS; POPULATION GENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE REARRANGEMENT; GENETIC COUNSELING; GERMANY; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMANS; MODELS, GENETIC; MUTATION; OVARIAN NEOPLASMS; PEDIGREE; PROBABILITY; ROC CURVE; SENSITIVITY AND SPECIFICITY; SOFTWARE;

EID: 84864668188     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-011-9498-y     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90
2. Zbuk K, Anand SS (2012) Declining incidence of breast cancer after decreased use of hormone-replacement therapy: Magnitude and time lags in different countries. J Epidemiol Community Health 66(1):1-7
3. Autier P, Boniol M, La Vecchia C et al (2010) Disparities in breast cancer mortality trends between 30 European countries: Retrospective trend analysis of WHO mortality database. BMJ 341:c3620
4. Jemal A, Center MM, DeSantis C, EM Ward (2010) Global patterns of cancer incidence, mortality rates, trends. Cancer Epidemiol Biomarkers Prev 19(8):1893-1907
5. Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity, penetrance analysis of the BRCA1, BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676-689
6. Carroll JC, Cremin C, Allanson J et al (2008) Hereditary breast and ovarian cancers. Can Fam Physician 54(12):1691-1692
7. Meindl A, Hellebrand H, Wiek C et al (2010) Germline mutations in breast, ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 42(5):410-414
8. Stegel V, Krajc M, Zgajnar J et al (2011) The occurrence of germline BRCA1, BRCA2 sequence alterations in Slovenian population. BMC Med Genet 12:9
9. Gadzicki D, Evans DG, Harris H et al (2011) Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, The Netherlands and Germany. J Community Genet 2:53-69
10. Amir E, Freedman OC, Seruga B, Evans DG (2010) Assessing women at high risk of breast cancer: A review of risk assessment models. J Natl Cancer Inst 102(10):680-691
11. Kuschel B, Hauenstein E, Kiechle M, Meindl A (2006) Hereditary breast and ovarian cancer-current clinical guidelines in Germany. Breast Care 1:8-14
12. Katki H (2007) Incorporating medical interventions into carrier probability estimation for genetic counseling. BMC Med Genet 8:13
13. Kurian AW, Gong GD, John EM et al (2009) Performance of prediction models for BRCA mutation carriage in three racial/ ethnic groups: Findings from the Northern California breast cancer family registry. Cancer Epidemiol Biomarkers Prev 18(4): 1084-1091
14. Schmutzler R, Beckmann M, Kiechle M (2002) Prevention: Hereditary breast and ovarian cancer. Dtsch Arztebl 99:A1372-A1378
15. Kreienberg R, Kopp I, Albert U et al. (2008) Interdisziplinare S3-leitlinie fur die diagnostik, therapie und nachsorge des mammakarzinoms. Munich, W. Zuckschwerdt Verlag GmbH
16. Bayraktar S, Elsayegh N, Gutierrez Barrera AM et al. (2011) Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer
17. Cremin C, Wong N, Buzaglo K, Paradis AJ, Foulkes W (2002) Nonovarian pelvic cancers in BRCA1/2 mutation carriers and the BRCAPRO statistical model. J Clin Oncol 20(18):3936
18. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44(3): 837-845
19. Antoniou AC, Hardy R, Walker L et al (2008) Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad, the Manchester scoring system using data from UK genetics clinics. J Med Genet 45(7):425-431
20. Kurian AW, Gong GD, Chun NM et al (2008) Performance of BRCA1/2 mutation prediction models in Asian Americans. J Clin Oncol 26(29):4752-4758
21. Lindor NM, Lindor RA, Apicella C et al (2007) Predicting BRCA1 and BRCA2 gene mutation carriers: Comparison of LAMBDA, BRCAPRO, Myriad II, and modified Couch models. Fam Cancer 6(4):473-482
22. Kang HH, Williams R, Leary J, Ringland C, Kirk J, Ward R (2006) Evaluation of models to predict BRCA germline mutations. Br J Cancer 95(7):914-920
23. Panchal SM, Ennis M, Canon S, Bordeleau LJ (2008) Selecting a BRCA risk assessment model for use in a familial cancer clinic. BMC Med Genet 9:116
24. Fasching PA, Bani MR, Nestle-Kramling C et al (2007) Evaluation of mathematical models for breast cancer risk assessment in routine clinical use. Eur J Cancer Prev 16(3):216-224
25. Beckmann MW, Bani MR, Fasching PA, Strick R, Lux MP (2007) Risk and risk assessment for breast cancer: Molecular and clinical aspects. Maturitas 57(1):56-60
26. Kast K, Schmutzler RK, Distler W et al. (2009) Prevalence rates of pathogenic mutations in the BRCA1 and BRCA2 genes in families with different disease histories: Results from the German consortium for hereditary breast and ovarian cancer. Cancer Res 69(24):731S-S
27. Backe J, Hofferbert S, Skawran B et al (1999) Frequency of BRCA1 mutation 5382insC in German breast cancer patients. Gynecol Oncol 72(3):402-406
28. Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1, BRCA2. Nat Genet 14(2):185-187
29. Vaidyanathan K, Lakhotia S, Ravishankar HM, Tabassum U, Mukherjee G, Somasundaram K (2009) BRCA1, BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations, high-frequency occurrence of 185delAG mutation. J Biosci 34(3):415-422
30. Mullineaux LG, Castellano TM, Shaw J et al (2003) Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado. Cancer 98(3):597-602
31. Zanna I, Rizzolo P, Sera F et al (2010) The BRCAPRO 5.0 model is a useful tool in genetic counseling, clinical management of male breast cancer cases. Eur J Hum Genet 18(7):856-858
32. Sluiter MD, van Rensburg EJ (2011) Large genomic rearrangements of the BRCA1, BRCA2 genes: Review of the literature, report of a novel BRCA1 mutation. Breast Cancer Res Treat 125(2):325-349
33. Engert S, Wappenschmidt B, Betz B et al (2008) MLPAscreening in the BRCA1 gene from 1, 506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, occurrence in single early-onset cases. Hum Mutat 29(7):948-958
34. Veschi S, Aceto G, Scioletti AP et al (2007) High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability. Ann Oncol 18(6):vi86-vi92